Here are four observations:
1. The increasing interest in tissue-engineered and stem cell products will boost the market’s growth.
2. Regenerative medicines’ potential in restoring diseased organs will elevate the market.
3. Cell therapy captured 80 percent of the U.S. regenerative medicine market in 2015.
4. Dominate market vendors include Acelity, Mesoblast, Organogenesis, Reprocell and Stryker.
More articles on biologics:
Smith & Nephew to purchase regenerative medicine company for $210M: 3 points
Anika Therapeutics appoints new chief human resources officer: 5 points
Dr. Alok Sharan presents results of novel surgical procedure at the NuVasive Spine Summit
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
